SCOTTSDALE, Ariz., Oct. 28, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming UBS Global Healthcare Conference, which will be hosted in Palm Beach Gardens, FL.
Details of the presentation are as follows:
Presenter: Dave Bourdon, CEO
Date: Monday, November 10, 2025
Time: 4:15 p.m. (Eastern time)
Moderated by: Kevin Caliendo
The presentation will be webcast live and will be available on the Events and Presentations section of the LifeStance Health Investor Relations website (https://investor.lifestance.com).
A replay of the webcast will be available after the conclusion of the event and can be accessed on the LifeStance Health Investor Relations website.
About LifeStance Health
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance and its supported practices employ approximately 7,700 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
Investor Contact:
Monica Prokocki
VP of Finance and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Brooke Matthews
Sr. Director of Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.10 |
| Daily Change: | -0.01 -0.20 |
| Daily Volume: | 800,877 |
| Market Cap: | US$1.980B |
October 28, 2025 August 26, 2025 August 07, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
